Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Metastatic Breast Cancer, Leptomeningeal...
Phase PHASE2
Enrollment 16
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: High-dose Methotrexate (8 gm/m2; HD-MTX) — Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.

Primary Outcomes

  • Overall Survival (at 12 weeks) (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2015-05
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Collaborators: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
Principal Investigators:
  • Roy Strowd, MD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Sara Cox
336-713-7748
Sara.Cox@advocatehealth.org
Strowd Roy, MD
rstrowd@wakehealth.edu
Joy Fisher
jfisher@jhmi.edu
Sidney Kimmel Comprehensive Cancer Center
Interventions
  • Drug: High-dose Methotrexate (8 gm/m2; HD-MTX) — Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
Study Locations (3 sites)
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21287 United States
Siteman Cancer Center- Washington University School of Medicine in St. Louis, St Louis, Missouri 63130 United States
Comprehensive Cancer Center at Wake Forest University (CCCWFU), Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria * Adults (male and female) age \>18 * Eastern Cooperative Group (ECOG) Performance Scale 0-1 (see Appendix I) * Histologically or cytologically confirmed invasive breast cancer of the following subtype: * TRIPLE NEGATIVE (ER-negative, PR-negative, and HER2-negative disease). Triple-negative patients will be defined per ASCO-CAP Guidelines. * HER2-POSITIVE: HER2-positive patients will be defined per ASCO-CAP Guidelines. * HORMONE REFRACTORY: Patients with ER/PR-positive disease according to ASCO-CAP guidelines above may be considered if they have disease progression after two lines of hormonal therapy (administered in the adjuvant or metastatic setting), or are deemed clinically hormone-resistant taking into consideration the rate of progression of disease or a short interval of time on first line hormonal therapy before progression. Clinically hormone-resistant patients MUST also be discussed with the Study Chair, Study co-chair or designee in advance for approval. NOTE: ASCO-CAP guidelines state that ER and PR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. HER2-positive is defined as HER2 IHC 3+, ISH ≥ 2.0, or average HER2 copy number ≥ 6.0 signals. NOTE: A patient who has a change in receptor status (e.g. PR negative to positive) may be stratified as triple negative or hormone positive, contrary to the most recent receptor testing, for the purposes of the study, based upon the clinical course at the discretion of the Study Chair, Study co-chair, or designee in advance for approval. * Cytologic or unequivocal radiographic confirmation of leptomeningeal metastasis by dural puncture and/or neuroimaging with or without known brain metastasis * Adequate organ function as follows: Estimated creatinine clearance \>70 cc/min (calculated by Cockcroft-Gault formula) White blood cell counts \>3000 cells/mcL Absolute neutrophil count \>1500 cells/mcL Platelet count \>100,000 cells/mcL Hematocrit \>30% Serum bilirubin \<1.5 x the ULN or \<5x the ULN if secondary to liver metastasis Alanine aminotransferase or aspartate aminotransferase \<2.5x the ULN or \<5x the ULN if secondary to liver metastasis Alkaline phosphatase \<2.5x the ULN or \<5x the ULN if secondary to liver metastasis \- Able to provide confirmed consent Exclusion Criteria * Prior allergy or adverse reaction to methotrexate * New York Heart Association Heart Failure Class \>3 * Active diabetes insipidus * Active mucositis * Chemotherapy or stereotactic radiotherapy within the last 2 weeks * Partial brain radiotherapy (i.e. \<40% of total brain volume) within the last 2 weeks * Whole brain radiotherapy within the last 6 months or partial brain radiotherapy exceeding \>40% of total brain volume within the last 6 months * Prior treatment with any methotrexate containing systemic regimen within 1 year (excluding intrathecal methotrexate) * Concurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti- HER2 directed therapy directed at management of breast cancer (existing anti-HER2 therapy can be continued as recently recommended in the National Consensus Guidelines (26) * Uncontrolled or progressive systemic disease or other concurrent condition which in the Investigator's opinion makes HD-MTX an undesirable treatment option for the patient or would jeopardize compliance * Contraindication to MRI * Use of salicylates, non-steroidal anti-inflammatory drugs, or sulfonamide medications within one week of start of methotrexate * Pregnant women or women who are breastfeeding. * Patients with significant visceral fluid collections including ascites, pericardial effusions, pleural effusions or others may experience delayed clearance of methotrexate because of third space accumulation which could result in methotrexate toxicity and inability to tolerate the proposed study treatment. While these are not absolute exclusions the Study Chair or co-Chairs should be contacted to discuss possible enrollment. Patients with significant ascites defined as European Association for the Study of the Liver \> grade 2 (Appendix IV), or with asymptomatic pleural effusions with an estimated size \>200 mL, or with symptomatic pleural effusion of any size will be excluded. NOTE: Systemic staging of the chest/abdomen/pelvis is required for study entry. See Sections 8.1.9. Body fluid will be assessed based on this study.
Conditions Breast Cancers
Phase PHASE1, PHASE2
Enrollment 161
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of the study is to explore the efficacy and safety of hyperbaric oxygen in the neoadjuvant treatment of breast cancer patients

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: hyperbaric oxygen treatment — Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).

Primary Outcomes

  • pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients (After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-02-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 161 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangdong Provincial People's Hospital
Principal Investigators:
  • Kun Wang, PhD (PRINCIPAL_INVESTIGATOR) - Guangdong Provincial People's Hospital Guangzhou,
Contact Information
Study Contact:
Kun Wang Kun Wang, PhD
+8615989223200
gzwangkun@126.com
Kun Wang Kun Wang
13922118086
gzwangkun@126.com
Guangdong Provincial People's Hospital
Kun Wang
13922118086
19zyzhuang@stu.edu.cn
Guangdong Provincial People's Hospital
Interventions
  • Device: hyperbaric oxygen treatment — Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
Study Locations (2 sites)
Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
Guangdong Provincial People's Hospital, Shantou, Guangdong 515041 China
Eligibility Criteria
Inclusion Criteria: 1. Understand the study process, participate in the study voluntarily, and sign the informed consent form. 2. patients with histopathologically confirmed initial unilateral primary invasive breast cancer, occult breast cancer, Patients with histopathologically confirmed initial unilateral primary invasive breast cancer, with the exception of occult breast cancer, inflammatory breast cancer and eczema-like carcinoma 3. aged ≥ 18 years and ≤ 60 years, female 4. patients who meet the inclusion criteria for neoadjuvant therapy to receive neoadjuvant therapy for breast cancer (locally advanced) Patients with locally advanced breast cancer (AJCC stage III, except T3N1M0) or operable breast cancer, but without breast-conserving or axillary preservation (stage IIA-IIB and T3N1M0) or HER2 positive or TNBC with certain tumour load, or patients with clinical lymph node positivity or tumour size of 2cm and above.) 5. ECOG performance status 0-1. 6. 6. LVEF ≥ 55% 7. 7. Adequate bone marrow functional reserve: white blood cell count ≥3.0 x 109/L, neutrophil count ≥1.5 x 109/L; and 1.5 x 109/L; platelet count ≥ 100 x 109/L; haemoglobin ≥ 90 g/L; 8. AST, ALT ≤ 2.5 times the upper limit of normal value, alkaline phosphatase ≤ 2.5 times the upper limit of normal value. Total bilirubin ≤ 1.5 times the upper limit of normal value; serum creatinine ≤ 1.5 times the upper limit of normal value. 9. For non-menopausal or non-surgically sterilised female patients: during treatment and at least 7 months after the last dose of study treatment. For non-menopausal or non-surgically sterilised female patients: consent to contraception during treatment and for at least 7 months after the last dose of study treatment. Exclusion Criteria: 1. Contraindication to hyperbaric oxygen therapy: untreated pneumothorax. Concurrent use of disulfiram. concomitant administration of anti-tumour drugs such as bleomycin, cisplatin, adriamycin concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. Premature and/or low body mass neonates. Lung disease (severe chronic obstructive pulmonary disease). Diseases of the lungs (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infections, uncontrolled asthma, uncontrolled diarrhoea). controlled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (eustachian tube Dysfunction of the eustachian tube, recurrent episodes of vertigo), ocular disease (retinal detachment). 2. previous hyperbaric oxygen therapy. 3. distant metastases, including lymph node metastases to the contralateral breast and mediastinum. 4. other malignant tumours within the last two years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix. Tumour. 5. pregnancy or lactation 6. uncontrolled hypertension, cardiac, hepatic, renal related disease or other medical or psychiatric conditions. 7. major surgical procedure unrelated to breast cancer within 4 weeks prior to randomisation, or the patient has not fully recovered from such procedure; or has not fully recovered from such surgical intervention. 8. serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to Serious or uncontrolled infections that may interfere with study treatment or the evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, and pulmonary infections. 9. recent history of thromboembolism and taking full dose anticoagulant medication. 10. any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study
Conditions Head and Neck Tumor, Breast Cancer
Phase NA
Enrollment 156
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy. The main pathways of RID is inflammation and oxidative stress on local and systemic bases. The Diclofenac is a COX-2 inhibitor and Nonsteroidal anti-inflammatory drugs whose anti-inflammatory and antioxidant activities have been proven in several clinical trials. Thus, the aim of the present study is to evaluate the efficacy of Diclofenac sodium gel as a prophylactic method against the development of RID.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Drug: Diclofenac Sodium Gel — Diclofenac Sodium Gel were applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.
  • Other: Placebo gel — The placebo does not contain the active ingredients of Jalosome, only the co-formulants.

Primary Outcomes

  • Incidence of development of grade ≥ 2 RID (From the first day of radiotherapy until 2 weeks after the end of radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-13
Completion: 2026-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Second Affiliated Hospital of Hainan Medical University
Contact Information
Study Contact:
yuecan zeng
19946610752
wellyy2005@hainmc.edu.cn
junnv xu
18208946196
xujunnv@sina.com
yuecan zeng, doctor
19946610752
wellyy2005@hainmc.edu.cn
The Second Affiliated Hospital of Hainan Medical University
Interventions
  • Drug: Diclofenac Sodium Gel — Diclofenac Sodium Gel were applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.
  • Other: Placebo gel — The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
Study Locations (1 sites)
The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311 China
Eligibility Criteria
Inclusion Criteria: 1. Male and female which are 18 years of age or older 2. Performance status \< 2 3. Epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinus and salivary glands or breast cancer, planned to receive a total dose of at least 50 Gy 4. The RTOG radiation dermatitis rating should be equal to 0 and the skin nutrition should be good 5. The main organs are functioning normally and meet the following standards: (1) Blood routine examination must meet the following criteria: (no blood transfusion within 14 days) a. HB ≥ 100g/L, b. WBC ≥3×10\^9/L c. ANC≥1.5×10\^9/L, d. PLT ≥100×10\^9/L; (2) Biochemical examination must meet the following standards: a. BIL\<1.5 times the upper limit of normal value (ULN), b. ALT and AST\<2.5ULN, GPT ≤1.5×ULN; c. Serum Cr≤1 ULN, endogenous creatinine clearance rate\>60ml/min (Cockcroft Gault formula);(3).Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;(4).The myocardial enzyme spectra were in the normal range. 6. Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the Clinical Investigation Plan tests and procedures. Exclusion Criteria: 1. Pregnant or lactating women 2. A known history of intolerance or allergy to any component of the investigational product; 3. severe cardiopulmonary disease (such as unstable angina attacks, grade II cardiac insufficiency, acute myocardial infarction, acute episodes of chronic obstructive pulmonary disease, pulmonary heart disease); 4. The acute phase is accompanied by inflammatory skin diseases, such as atopic dermatitis, contact dermatitis, psoriasis, lichen planus, pityriasis rosea. 5. Systemic diseases known to delay the skin healing process, such as diabetes or severe kidney failure; 6. Skin rupture caused by malignant tumors.
Conditions Mammaplasty, Breast Cancer, Poland Syndr...
Phase NA
Enrollment 66
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The present study will be based on a hybrid breast reconstruction approach with initial skin expansion using the Motiva Flora® Tissue Expander followed by a serial fat grafting session and a final step that includes the placement of a permanent breast implant Ergonomix2®.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Motiva Flora® Tissue Expander — This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant. Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication. To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study.

Primary Outcomes

  • Total adverse envent rate (46 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-18
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Establishment Labs
Collaborators: NAMSA
Contact Information
Study Contact:
Lilián Patricia Palma López
+34649713486
lpalma@establishmentlabs.com
Laura García Jimenez
lgarcia@establishmentlabs.com
Filip Stillaert, PhD. MD.
stillaert@me.com
Universitair Ziekenhuis Gent
Interventions
  • Device: Motiva Flora® Tissue Expander — This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant. Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication. To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study.
Study Locations (4 sites)
Universitair Ziekenhuis Gent, Ghent, Belgium
Hospital Universitario San Ignacio, Bogotá, Colombia
Hospital UNIBE, San José, Costa Rica
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Eligibility Criteria
Inclusion Criteria: 1. Genetically female, aged 18 years or older. 2. Subjects who had provided written informed consent form. 3. The participant needs tissue expansion as part of breast reconstruction treatment, which may include immediate reconstruction. 4. Clinical condition to allow reverse expansion breast reconstruction, at the investigator's discretion. 5. Sufficient fat in donor sites (abdomen, gluteus, hips, and thighs) per plastic surgeon criteria. 6. Complete radiotherapy and chemotherapy at least one year before surgery. 7. BMI between 18.5 and 30.0 (average classified weight). 8. Physical and cognitive capacity to understand and follow the surgeon's recommendations. 9. To be able and willing to comply with all study requirements, including attending follow-up appointments. Only Sub study participants 10. Provide additional consent to undergo an MRI with contrast. Exclusion Criteria: 1. Current pregnancy or lactation, or full-term pregnancy or lactation at any point during the clinical investigation. 2. Abnormal hematological and biochemical values after chemotherapy. 3. High surgical risk according to the investigator. 4. Breast width larger than 18 cm 5. Tumor residues in or near the area where tissue expansion is performed. 6. Subjects with metastatic breast cancer 7. Significant Breast ptosis or poor skin quality 8. Participants who do not have adequate tissue at the intended site for expansion, at the surgeon's discretion, due to previous radiotherapy, ulceration, vascular involvement, history of impaired wound healing, or mastectomy scar deformity. 9. Inadequate chest wall tissue due to damage caused by radiotherapy, tight skin grafts, or radical resection of the pectoralis major muscle. 10. Current or previous infection in the area where the expansion occurs. 11. Any condition that impedes magnetic resonance imaging (MRI), including implanted metal device, claustrophobia, or other ailments that would prohibit MRI scan. 12. Presence of autoimmune diseases such as lupus or scleroderma, or immunocompromised participants due to immunosuppressive or steroid therapy. 13. History of silicone sensitivity. 14. Active smokers 15. Previous attempts of breast reconstruction 16. Subjects who, in the opinion of the investigator, are considered part of any vulnerable population 17. Subjects with affiliation to the Sponsor, sites or investigators, including relatives. 18. Participants who do not live in the procedure's country make it impossible to assist in follow-up visits. 19. Subjects who are participating in other investigation(s) which may affect the outcomes or ability to comply follow-up requirements of this study
Conditions Breast Cancer, Anxiety, Mastectomy, Pati...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the impact of artificial intelligence (AI)-supported preoperative education on fear and anxiety levels in patients undergoing total mastectomy. It is a randomized controlled trial involving two groups: one receiving AI-supported education and the other receiving standard preoperative education. The primary outcomes are to assess changes in surgical fear and anxiety levels. The study targets adult female patients diagnosed with breast cancer who are scheduled for total mastectomy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: AI-Supported Preoperative Education — This intervention involves the use of a pre-trained AI-powered education platform designed to provide preoperative information to patients undergoing mastectomy. The program delivers structured, interactive education that includes details about the surgical process, postoperative care, and emotional coping strategies. The pre-trained AI system offers standardized responses to patient questions, ensuring consistency and clarity in the information provided, with the goal of reducing fear and anxiety.
  • Behavioral: Standard Preoperative Education — This intervention consists of standard preoperative education provided by healthcare professionals. Patients receive general information about the surgical procedure, postoperative care, and strategies to manage fear and anxiety. The education is delivered in a traditional, face-to-face format without the use of AI or digital tools.

Primary Outcomes

  • Surgical Fear Questionnaire / SFQ (The scales will be administered twice: 15 minutes before the preoperative education session and 15 minutes after the preoperative education session.)
  • State-Trait Anxiety Inventory /STAI (The scales will be administered twice: 15 minutes before the preoperative education session and 15 minutes after the preoperative education session.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2025-08-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bezmialem Vakif University
Collaborators: Acibadem University
Principal Investigators:
  • Mahmut DAGCI, PhD (PRINCIPAL_INVESTIGATOR) - Bezmialem Foundation University
Contact Information
Study Contact:
Mahmut DAĞCI, PhD
+90 05547618939
MDagci@bezmialem.edu.tr
Gamze ORHAN, M. Sc.
+90 5302473293
orhangamze34@gmail.com
Gamze Orhan, Nurse
+90 5302473293
orhangamze34@gmail.com
Acibadem International Hospital
Interventions
  • Behavioral: AI-Supported Preoperative Education — This intervention involves the use of a pre-trained AI-powered education platform designed to provide preoperative information to patients undergoing mastectomy. The program delivers structured, interactive education that includes details about the surgical process, postoperative care, and emotional coping strategies. The pre-trained AI system offers standardized responses to patient questions, ensuring consistency and clarity in the information provided, with the goal of reducing fear and anxiety.
  • Behavioral: Standard Preoperative Education — This intervention consists of standard preoperative education provided by healthcare professionals. Patients receive general information about the surgical procedure, postoperative care, and strategies to manage fear and anxiety. The education is delivered in a traditional, face-to-face format without the use of AI or digital tools.
Study Locations (1 sites)
Acibadem International Hospital, Istanbul, Bakirköy 34149 Turkey (Türkiye)
Eligibility Criteria
Inclusion criteria: * Literate female patients * Patients who will undergo total mastectomy surgery * Patients diagnosed with breast cancer * Patients who are over 18 years of age * Patients who agree to participate in the study and from whom written consent has been obtained will be included in the study. Exclusion criteria: * Patients who cannot understand or communicate in Turkish * Patients with active psychiatric disorders (e.g., major depression, bipolar disorder, schizophrenia) * Patients with advanced hearing or vision problems * Patients with mental disabilities * Patients who have previously participated in a similar training program will be excluded from the study.
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase PHASE2
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the efficacy and safety of SHR-A1811 plus pertuzumab in combination with or without albumin-paclitaxel neoadjuvant therapy for early or locally advanced HER2-positive breast cancer. The main questions it aims to answer are: * Does the pCR of SHR-A1811 plus pertuzumab with or without albumin-paclitaxel improve compared to the current standard of treatment? * Is the safety of SHR-A1811 plus pertuzumab with or without albumin-paclitaxel better compared to the current standard of treatment? Researchers will compare SHR-A1811+pertuzumab or SHR-A1811+pertuzumab+albumin-paclitaxel to TCbHP to see if SHR-A1811 plus pertuzumab with or without albumin-paclitaxel works to treat early or locally advanced HER2-positive breast cancer. Subjects will be randomly assigned 1:1:1 to: * cohort 1:SHR-A1811 combined with pertuzumab for 6 cycles; * cohort 2:SHR-A1811 combined with pertuzumab and albumin-paclitaxel for 6 cycles; * cohort 3:TCbHP (docetaxel, carboplatin, trastuzumab and pertuzumab) for 6 cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SHR-A1811 — an anti-HER2 antibody-drug conjugate (ADC)
  • Drug: Pertuzumab — Pertuzumab
  • Drug: Albumin-Paclitaxel — Nab paclitaxel
  • Drug: Docetaxel — Docetaxel
  • Drug: Carboplatin — Carboplatin
  • Drug: Trastuzumab — Trastuzumab

Primary Outcomes

  • Pathological complete response rate (pCR rate) (After surgery(within 1 month))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-16
Completion: 2030-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Principal Investigators:
  • Zhenzhen Liu (PRINCIPAL_INVESTIGATOR) - Henan Cancer Hospital
Contact Information
Study Contact:
Zhenzhen Liu
86+13603862755
liuzhenzhen73@126.com
Interventions
  • Drug: SHR-A1811 — an anti-HER2 antibody-drug conjugate (ADC)
  • Drug: Pertuzumab — Pertuzumab
  • Drug: Albumin-Paclitaxel — Nab paclitaxel
  • Drug: Docetaxel — Docetaxel
  • Drug: Carboplatin — Carboplatin
Study Locations (1 sites)
Henan Cancer Hospital, Zhengzhou, Henan China
Eligibility Criteria
Inclusion Criteria: * Age: 18-70 years old, ECOG 0-1 point. * Clinical T2-T4, with any LN, M0. * HER2+, invasive breast cancer confirmed by histopathology;(HER2 positive expression means that there is at least one case of tumor cell immunohistochemical staining intensity of 3+or positive confirmed by fluorescence in situ hybridization \[FISH\] in the pathological test/review of the primary focus conducted by the Pathology Department of the Research Center Hospital). * Having clinically measurable lesions: measurable lesions displayed on ultrasound, mammography, or MR (optional) within the first month of randomization. * Organ and bone marrow function tests within one month before chemotherapy indicate no contraindications to chemotherapy:Absolute value of neutrophil count ≥ 1.5 × 10\^9/L; Hemoglobin ≥ 90g/L; Platelet count ≥ 100 × 10\^9/L; Total bilirubin≤1.5 ULN (upper limit of normal value); Creatinine≤1.5 × ULN; AST/ALT ≤ 2.5 × ULN. * Cardiac ultrasound: Left ventricular ejection fraction (LVEF ≥ 50%). * Women of childbearing age tested negative for serum pregnancy test 7 days before randomization. * Sign an informed consent form. Exclusion Criteria: * Stage IV (metastatic) breast cancer. * Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease. * The patient has a second primary malignant tumor, except for fully treated skin cancer. * The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical procedures. * The presence of uncontrolled cardiovascular and cerebrovascular disease, including (but not limited to) any of the following within the 6 months prior to the first dose: congestive heart failure (NYHA III or IV), myocardial infarction or cerebral infarction, pulmonary embolism, unstable angina, or arrhythmia requiring treatment at the time of screening; Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restricted cardiomyopathy, undefined cardiomyopathy); A clinically significant history of prolonged QTc, grade II type II atrioventricular block or grade III atrioventricular block or QTc interphase (F method) \> 470 msec (female); Atrial fibrillation (EHRA grade ≥2b); Unmanageable hypertension, which the investigators judged unsuitable for study participation. * Due to serious and uncontrollable other medical diseases, researchers believe that there are contraindications to chemotherapy. * Individuals with a known history of allergies to the drug components of this protocol; * Having a history of immunodeficiency, including HIV testing positive, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.
Conditions Early Breast Cancer
Phase PHASE2
Enrollment 105
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Social determinants such as education, income, marital status, and social networks play a crucial role in cancer outcomes, including breast cancer. One potential influencing factor is diet, and the Mediterranean diet has been shown to benefit both the health and the microbiome. This raises the question: Does adherence to the Mediterranean diet impact the microbiome, quality of life, overall well-being, and outcomes in breast cancer patients undergoing (neo)adjuvant treatment, particularly among those with unfavorable socioeconomic determinants? The Mediterranean diet consists of plant foods such as vegetables, fruits, nuts, seeds, berries, legumes, herbs, and spices. It also features animal proteins like fish, meat, and cheese, along with fat from olive oil. Thus, adherence to the Mediterranean diet is adherence to the official Danish diet recommendations. This phase II clinical trial is an interdisciplinary study combining nutrition, sociology, and health research. Breast cancer patients candidates for (neo)adjuvant treatment at four oncology departments in Region South Denmark will be randomized 2:1 to the Mediterranean diet (with individual dietary guidance from a nutrition therapist aiming at daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food) versus the patient's regular diet, in conjuction with the (neo)adjuvant chemotherapy. The trial's primary endpoint will be changes in gut microbiota composition in feces. The study evaluates how the Mediterranean diet affects the microbiota (evaluated using Oxford Nanopore Technology 16S sequencing on fecal samples); short-chain fatty acids in stool and plasma (assessed by mass spectrometry); immune system (using flow cytometry for immune cell determination in blood and immunohistochemical determination of immune cells in the tumor tissue); and patients' social quality of life, overall well-being, sense of empowerment, and personal feeling of agency (using the WHOQOL-100 questionnaire); taking into account the impact of the distance from the patient residence to the hospital (tracked from GEOTEAM at Statistics Denmark), and socioeconomic factors (using the DREAM database). The evaluation of biological parameters is based on the suggested mechanism of action. A diet rich in various plant foods and dietary fiber will alter the gut microbiota, promoting bacteria producing high amounts of short-chain fatty acids. These fatty acids will activate immune cells, aiding in the destruction of cancer cells. The study will also assess whether the Mediterranean diet will positively impact the patients' social quality of life, overall well-being, sense of empowerment, and personal feeling of agency. The Mediterranean diet may not only lead to improved dietary habits but also serve as a crucial tool for breast cancer patients, particularly among those with unfavorable socioeconomic…

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: The goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food. — The intervention group will receive personalized education and guidance from a nutrition therapist.
  • Other: Standard Diet — The control group will continue their normal diet, and not receive guidance or participate in group sessions.

Primary Outcomes

  • Change in microbiota composition (Baseline to Day 1 of chemotherapy cycle 6. Each cycle is 3 weeks for regular schedule or 2 weeks for accelerated schedule, as per clinician decision.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-27
Completion: 2036-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark
Collaborators: Vejle Hospital, Hospital of Southern Jutland, Odense University Hospital, Syddansk Universitet, Denmark, University of Copenhagen, Aarhus University Hospital, Danish Breast Cancer Cooperative Group, Aalborg University
Contact Information
Study Contact:
Frede Donskov, Clinical Professor, MD, DMSc,
+45 2053 3235
fdonskov@health.sdu.dk
Lone Gamrath, PhD Fellow
+45 2920 3221
Lone.Gamrath@rsyd.dk
Erik H Jakobsen, MD
+45 7997 3036
erik.hugger.jakobsen@rsyd.dk
Hospital of Southern Jutland
Interventions
  • Dietary Supplement: The goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food. — The intervention group will receive personalized education and guidance from a nutrition therapist.
  • Other: Standard Diet — The control group will continue their normal diet, and not receive guidance or participate in group sessions.
Study Locations (3 sites)
Hospital of Southern Jutland, Sønderborg, Southern Denmark 6400 Denmark
University Hospital of Southern Denmark, Esbjerg, Esbjerg, 6700 Denmark
Sygehus Lillebaelt, Vejle, Vejle, 7100 Denmark
Eligibility Criteria
Inclusion Criteria: 1. Signed written informed consent approved by the Ethical Review Board. 2. Age ≥ 18 3. Histologically confirmed unilateral adenocarcinoma of the breast, stage I-III, candidates for neoadjuvant chemotherapy followed by curative surgery, or adjuvant chemotherapy after curative surgery, according to the Danish Breast Cancer Group guidelines 48. The addition of trastuzumab and pertuzumab in HER2-positive tumors, or pembrolizumab in triple-negative tumors, per Danish Breast Cancer Group guidelines 48, is allowed as an adjunct to chemotherapy. 4. Good performance status (WHO performance status 0 or 1). 5. Willingness by the patient to undergo treatment and study-related procedures according to the protocol. 6. Have a smartphone or computer to which it is possible to receive emails (for food diary; www.myfood24.org) 7. Must be willing to restrict from probiotic (living microorganisms) supplements during the study. Fermented foods are allowed. \- Exclusion Criteria: 1. Clinical or radiological signs of metastatic disease. 2. History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin cancer. 3. Previous chemotherapy for cancer or other malignant disease. 4. Major altered digestive system disorders (e.g. gastric by-pass or Crohn's disease or ulcerative colitis) 5. Unable to communicate effectively in Danish or English.
Conditions Gynecologic Cancers, Breast Cancer
Phase PHASE1
Enrollment 60
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to plan for a large scale evaluation of a program called Mindful After Cancer, or MAC. The MAC Program provides training in mindfulness, educational material about sexual health after cancer, and support to cancer survivors experiencing sexual and body image concerns. The main study aims are to: 1. Develop effective plans for recruiting participants across multiple sites 2. Evaluate participation in the program and surveys 3. Develop plans to train and supervise the professionals who will deliver the program. Researchers will compare study recruitment across three sites, aiming to identify the most efficient approach for a larger future trial. Participants who are randomly assigned to receive the MAC program will receive access to the 8-week program delivered by a trained mindfulness coach using videoconference and online materials. They will asked to participate in an interview about their experiences at the end of the program. Participants who are not randomly assigned to the MAC program will receive access to the program's educational materials after completing the final survey. All study participants will be asked to complete 3 online surveys. Participants randomly assigned to the MAC Program will also be asked to complete a one-on-one interview about their experience in the program.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Mindful After Cancer Program — The Mindful After Cancer Program provides education, mindfulness training, and peer support to help cancer survivors navigate sexual and body image concerns.

Primary Outcomes

  • Recruitment Accrual Rate- The percent of eligible candidates who enroll (Baseline)
  • Intervention Fidelity- The percent of required topics covered during intervention sessions as measured by completion of a checklist. (Up to 1 week post-intervention.)
  • Retention Rate - The percent of enrolled participants who complete all study surveys (Up to the 3 month post-intervention survey at week 22.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-09-30
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oregon State University
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Jessica Gorman, PhD
541-737-2323
Jessica.Gorman@oregonstate.edu
Jonathan Wakefield
541-737-1064
wakefjon@oregonstate.edu
Samaritan Pastega Regional Cancer Center
Hannah Toneff
267-882-3186
hannah.toneff@pennmedicine.upenn.edu
University of Pennsylvania
Interventions
  • Behavioral: Mindful After Cancer Program — The Mindful After Cancer Program provides education, mindfulness training, and peer support to help cancer survivors navigate sexual and body image concerns.
Study Locations (3 sites)
Samaritan Pastega Regional Cancer Center, Corvallis, Oregon 97330 United States
University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 United States
Eligibility Criteria
Inclusion Criteria: * At least 18 years old * Diagnosed with female breast or gynecologic cancer at stage I-IV * Diagnosed at least 6 months ago * At least one sexual concern in a validated screener * Access to high speed internet via smart phone, tablet, and/or computer Exclusion Criteria: • Those who do not comprehend English since the MAC program is only available in English.
Conditions Type 2 Diabetes, Lifestyle-related Condi...
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

A recognized driver for cardiovascular complications of type 2 diabetes mellitus (T2DM) is impaired plasma glucose homeostasis as consequence of skeletal muscle insulin resistance. Insulin-mediated plasma glucose disposal in skeletal muscle comprises oxidative glucose disposal (cellular glucose uptake for oxidation) and non-oxidative glucose disposal (NOGD; cellular glucose uptake for storage as glycogen), both processes being impaired in T2DM patients. Excessive intrahepatic fat accumulation (particularly monounsaturated (MUFA) and saturated (SFA)) is commonly observed in T2DM patients and tightly associates with plasma glucose dysregulation. It has been hypothesized that skeletal muscle insulin resistance redistributes circulating glucose away from muscle which together with hyperinsulinemia promotes intrahepatic lipid accretion via de novo lipogenesis (DNL). As saturated lipids is the final product of DNL, improving skeletal muscle insulin sensitivity, next to enhance plasma glucose homeostasis, might lower intrahepatic lipid content particularly intrahepatic saturated lipids. Regular exercise is a cornerstone in the treatment of T2DM and to improve skeletal muscle insulin sensitivity. Interestingly, a conventional exercise program (aerobic-type combined with strength-type exercise) restores insulin-stimulated oxidative glucose disposal in T2DM patients to levels observed in age-matched normoglycemic subjects. Non-oxidative glucose disposal (NOGD), however, does not improve upon such conventional exercise programs. In this regard, for full restoration of compromised glucose disposal, it is pivotal to come up with effective training methods to target NOGD. High intensity interval training (HIIT) has the potential to expands the glycogen synthesis capacity in athletes by repetitive cycles of glycogen depletion/repletion, hence holds promise to improve NOGD in T2DM patients. Of note, HIIT also lowers the intrahepatic fat content in pre-diabetes individuals. Nevertheless, whether HIIT reduces the intrahepatic fat content and modifies its composition in T2DM patients is unknown. In this regard, it is hypothesized that HIIT expands the NOGD capacity in skeletal muscle of overweight/obese type 2 diabetes patients. By doing so, it is postulated that HIIT improves skeletal muscle insulin sensitivity and therefore benefits the 24 hours glycaemic profile in T2DM patients. In line, it is hypothesized that the HIIT-mediated improvements on NOGD and skeletal muscle insulin sensitivity coexist with the reduction of intrahepatic lipid content -particularly reduced saturated lipids- via lowering DNL.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Experimental group: Exercise training — HIIT program, 3 times per week for 12 weeks

Primary Outcomes

  • Insulin-stimulated non-oxidative plasma glucose disposal (NOGD) (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2026-12-31
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Finis Terrae University
Principal Investigators:
  • Rodrigo Mancilla, PhD (PRINCIPAL_INVESTIGATOR) - Finis Terrae University
Contact Information
Study Contact:
Rodrigo Mancilla, PhD
+56953676588
rmancilla@uft.cl
Rodrigo Mancilla, PhD
Finis Terrae University
Interventions
  • Other: Experimental group: Exercise training — HIIT program, 3 times per week for 12 weeks
Study Locations (1 sites)
Finis Terrae University, Santiago, Chile
Eligibility Criteria
Inclusion Criteria: * Participants are able to provide signed and dated written informed consent prior to any study specific procedures * Aged ≥ 45 and ≤ 75 years * BMI: 25-35 kg/m2 * Diagnosed as T2DM patients for at least 1 year and not longer than 5 years * HbA1c ≥ 6.5% and ≤ 8.5% * Fasting blood glucose \<130 mg/dL * Women are post-menopausal (\>1 year cessation of menses), * Being stable on medication use of metformin and/or sulfonylurea derivatives for the previous 3 months or more and other medication naïve. Exclusion Criteria: * Type 1 diabetes * Patients with congestive heart failure and and/or severe renal and or liver insufficiency * Contraindications for MRI/MRS examination * Active diabetic foot * Polyneuropathy or retinopathy * Signs of active liver or kidney dysfunction * BMI \>35 kg/m2 * Exogeneous insulin therapy * Use of antidiabetic medication other than metformin or sulfonylurea derivatives treatment within 3 months before screening * Use of SGLT2 inhibitors * Unstable body weight (variations \>5kg in the last 3 months) * Ongoing weight loss diet or use of weight loss agents * Uncontrolled hypertension * Engagement in regular exercise program or any other medical condition that will impede the safe performance of the experiments
Conditions Obesity, Type2diabetes, Gut Microbiota, ...
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The role of intestinal microbiota is becoming ever more important in the context of obesity, type II diabetes (T2D), and infectious disorders as represented by the emerging discipline "therapeutic microbiology". The gut microbiota is strictly interconnected with obesity and T2D playing also an important role in immune system regulation. Obesity and diabetes can lead to chronic inflammation, which results in the secretion of pro-inflammatory cytokines like IL-6, IL-1, and TNF-alpha, causing immune system alteration which predisposes patients with obesity and T2D to chronic infections. Therefore, the principal aim of the study is to investigate changes in gut microbiota composition between patients with chronic infections or not, so as to attribute to specific phyla the formation of the infections in these patients.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Observational — No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.

Primary Outcomes

  • Omic signature differences between group of case and group of control (Changes in microbiota composition between time 0 months (start point of the study) and 12 months (end point of the study))
  • Immune system differences between group of case and group of control (Changes in the level and type of pro-inflammatory cytokines between basal time, 0 months , 6 and 12 months (end of the study) in both case and control group)
  • Patient card for the evaluation of the pharmacological therapy (changes between time 0 months (basal time) and 12 months (end of the study))
  • Identification of the oral microbiota (changes in oral microbiota between the two different groups at time 0 months, 6 months and 12 months)
  • Number of white blood cells (changes in WBC biochemical levels between time 0 months, 6 months and 12 months in both case and control groups)
  • Blood cells count (changes in blood cells count between time 0 months, 6 months and 12 months in both case and control group)
  • Lipid profile identification (changes in lipid profile between time 0 months, 6 months and 12 months in both case and control group)
  • Uric acid concentration (changes in uric acid levels between time 0 months, 6 months and 12 months in both case and control group)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-01
Completion: 2027-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita
Contact Information
Study Contact:
Flavia Prodam, Prof.MD
+39 0321 660 693
flavia.prodam@med.uniupo.it
Flavia Prodam, Prof.MD
+39 0321 660 693
flavia.prodam@med.uniupo.it
Maggiore della Carità Hospital
Interventions
  • Other: Observational — No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
Study Locations (1 sites)
Maggiore della Carità Hospital, Novara, Novara 28100 Italy
Eligibility Criteria
Inclusion Criteria: * age between 18-65 years * ability to understand the study protocol * obesity with BMI between 30-40 kg/m2 * affects by type II diabetes * presence/absence of chronic infections * the possibility of equality in the two groups (matched for sex, age, and therapies) Exclusion Criteria: * psychological conditions that reduced the ability the comprehension of the study protocol * subjects undergoing a diet-therapeutic regimen; * subjects with the possibility of developing diabetic foot in the successive months * patients with relapsing infections * pregnancy * bariatric surgery * oncological and hematological pathologies * Hypogonadism * severe immunodepression * vaccination in the last two weeks * Alcohol or drug abuse * antibiotic therapy
Conditions Chronic Obstructive Pulmonary Disease (C...
Phase Not Applicable
Enrollment 2000
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated. Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will be collected at 1-, 3-, 6-, 9- and 12-months after hospital discharge. Biospecimens, including blood and bronchoalveolar lavage fluid, will be collected and analyzed for biomarker detecting. Primary outcome are length of hospital stay and re-exacerbation during fellow-up. Secondary outcomes include comorbidity pattern and its impact on respiratory symptoms burden, quality of life, pulmonary function and chest imaging as well as cost and healthcare utilization. Conclusions: The knowledge generated from CAM cohort study will fill crucial gaps in understanding how multimorbidity affects CAD and facilitate evidence-based clinical practice in the future.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Length of hospital stay (From the date of admission until discharge or death, assessed over an estimated period of 3 to 30 days.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-01
Completion: 2028-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China-Japan Friendship Hospital
Collaborators: Second Affiliated Hospital of Xi'an Jiaotong University, First Hospital of China Medical University, Henan Provincial People's Hospital, Second Xiangya Hospital of Central South University, Sichuan University, Southern Medical University, China, Ruijin Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Principal Investigators:
  • Ting Yang, MD (PRINCIPAL_INVESTIGATOR) - China-Japan Friendship Hospital, National Center for Respiratory Medicine
Contact Information
Study Contact:
Ke Huang, MD.
+8615120079197
huangke_zryy@163.com
Wei Li, MD.
+8615910971249
412633088@qq.com
Ke Huang, MD
+86-15120079197
huangke_zryy@163.com
National Center for Respiratory Medicine, China-Japan Friendship Hospital
Interventions
N/A
Study Locations (9 sites)
National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, Beijing Municipality 100029 China
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510280 China
Henan Provincial People's Hospital, Zhengzhou, Henan 450003 China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022 China
The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011 China
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001 China
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710114 China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai Municipality 200025 China
West China Hospital of Sichuan University, Chengdu, Sichuan 610041 China
Eligibility Criteria
Inclusion Criteria: * Patients with chronic obstructive pulmonary disease ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age; * The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis". Exclusion Criteria: * Patients were unable to undergo spirometry during the stabilization period; * Expected survival is less than 1 month; * Refusal to sign an informed consent form; * Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion; * Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation.
Conditions Eosinophilic Asthma
Phase PHASE3
Enrollment 400
Locations 160 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Combination Product: ICS-LABA — ICS-LABA inhalation
  • Combination Product: benralizumab — Benralizumab. SC injection.
  • Combination Product: Placebo for Benralizumab — Placebo for Benralizumab (aka, "placebo"). SC injection.

Primary Outcomes

  • Annualized asthma exacerbation rate (Baseline through Week 48)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-28
Completion: 2028-11-03
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Combination Product: ICS-LABA — ICS-LABA inhalation
  • Combination Product: benralizumab — Benralizumab. SC injection.
  • Combination Product: Placebo for Benralizumab — Placebo for Benralizumab (aka, "placebo"). SC injection.
Study Locations (160 sites)
Research Site, Chandler, Arizona 85224 United States
Research Site, Sun City, Arizona 85351 United States
Research Site, Tucson, Arizona 85704 United States
Research Site, Bakersfield, California 93301 United States
Research Site, Inglewood, California 90301 United States
Research Site, Modesto, California 95355 United States
Research Site, Newport Beach, California 92663 United States
Research Site, Pasadena, California 91101 United States
Research Site, Denver, Colorado 80206 United States
Research Site, Cape Coral, Florida 33990 United States
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Participant must be 12 to 75 years of age * Documented history of physician-diagnosed asthma requiring treatment with at least medium-dose ICS (\> 250 μg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit (V) 1. * Documented treatment with medium-dose ICS and LABA for at least 3 months prior to Visit 1 with or without additional asthma controllers (excluding oral corticosteroids). * Weight of ≥ 35 kg. * Pre-Bronchodilator (BD) Forced expiratory volume in 1 second (FEV1) of ≤ 90% predicted * Documented at least 2 asthma exacerbations in the 12 months prior to the date of informed consent. * ACQ-6 score ≥ 1.5 at Visit 1, plus at least once in the run-in period (from V2 to V3) and at V3. * Evidence of asthma as documented by excessive variability in lung function, as defined in the protocol. * Peripheral blood eosinophil count of ≥ 150 cells/μL, as defined in the protocol. * At least 70% compliance with usual asthma controller ICS-LABA during run-in period (from Visit 2 to Visit 3) based on asthma daily diary. Exclusion Criteria: * Important pulmonary disease other than asthma at the discretion of the investigator, or ever been diagnosed with pulmonary or systemic disease, other than asthma, which are associated with elevated peripheral eosinophil counts. * Asthma exacerbation requiring use of Systemic corticosteroids (SCS), or acute upper/lower respiratory infection that requires antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period * Any unstable disorder that in the opinion of the investigator could affect the study according to the study protocol. * Clinically significant chronic or ongoing active infections requiring systemic treatment (at investigator's discretion) * Concurrent participation in another clinical study with an IP or a post-authorisation safety study. * History of alcohol or drug abuse within 12 months prior to the date informed consent is obtained. * Current smokers or former smokers with a smoking history ≥ 10 pack-years. Former smokers must have stopped for at least 6 months prior to Visit 1 to be eligible.